Prime Medicine, Inc. (PRME) Key Metrics
PRME valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $629.4M
- Enterprise value
- $622.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 154.5 10-yr median 116.1
- Price / book
- 0.3 10-yr median 5.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.38
PRME key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPRME valuation Price multiples at each fiscal year-end price.
PRME returns How much profit the business earns on the capital it uses.
PRME per-share figures Results divided by the shares outstanding at year-end.
PRME financial health Debt, liquidity and how easily interest is covered.
PRME efficiency & capital use Working capital cycle and where the cash goes.
PRME valuation history
PRME returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRME debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRME price vs earnings per share
PRME key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $516.2M | $346.3M | $806.0M | $1.81B | — | — | — |
| Enterprise value | $454.9M | $196.7M | $698.0M | $1.54B | — | — | — |
| Price / sales | 111.4 | 116.1 | — | 346.7 | — | — | — |
| Price / book | 4.3 | 2.3 | 6.1 | 5.7 | — | — | — |
| EV / sales | 98.2 | 65.9 | — | 295.8 | — | — | — |
| Earnings yield | −39.0% | −56.6% | −24.6% | −6.7% | — | — | — |
| Free cash flow yield | −32.4% | −37.6% | −21.6% | −8.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — | — |
| Share price at fiscal year-end | $3.47 | $2.92 | $8.86 | $18.58 | — | — | — |
| Per share | |||||||
| Revenue per share | $0.03 | $0.03 | $0.00 | $0.05 | $0.00 | $0.05 | $0.00 |
| Earnings per share | −$1.35 | −$1.65 | −$2.18 | −$1.25 | −$1.73 | −$0.04 | −$0.03 |
| Operating cash flow per share | −$1.09 | −$1.04 | −$1.82 | −$1.36 | −$0.36 | −$0.06 | −$0.01 |
| Free cash flow per share | −$1.12 | −$1.10 | −$1.91 | −$1.52 | −$0.40 | −$0.06 | −$0.01 |
| Cash per share | $1.19 | $1.61 | $1.34 | $3.02 | $2.82 | $0.56 | $0.09 |
| Book value per share | $0.81 | $1.29 | $1.46 | $3.25 | $2.50 | $0.35 | $0.01 |
| Tangible book value per share | $0.81 | $1.29 | $1.46 | $3.25 | $2.50 | $0.35 | $0.01 |
| Capex per share | $0.03 | $0.06 | $0.10 | $0.17 | $0.04 | $0.01 | $0.01 |
| Debt per share | $0.78 | $0.34 | $0.15 | $0.30 | $0.11 | $0.18 | — |
| Shares outstanding | 148.8M | 118.6M | 91.0M | 97.2M | 95.7M | 95.7M | 95.7M |
| Change in shares outstanding | +25.4% | +30.4% | −6.4% | +1.5% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −146.8% | −136.9% | −88.2% | −43.8% | −121.1% | −19.6% | −182.1% |
| Return on invested capital (ROIC) | −521.6% | — | −425.0% | −585.7% | — | — | — |
| Return on assets (ROA) | −62.8% | −79.7% | −71.5% | −36.8% | −92.7% | −10.7% | −29.1% |
| Return on tangible assets | −58.7% | −65.8% | −102.2% | −33.8% | −54.8% | −6.2% | −29.1% |
| Free cash flow margin | — | — | — | — | — | −118.7% | — |
| Financial health | |||||||
| Total debt | $116.4M | $40.8M | $13.6M | $28.7M | $10.4M | $17.5M | — |
| Cash & short-term investments | $177.7M | $190.4M | $121.7M | $293.9M | $269.6M | $53.3M | $8.6M |
| Net debt | −$61.3M | −$149.6M | −$108.0M | −$265.2M | −$259.2M | −$35.8M | −$8.6M |
| Debt / equity | 0.96 | 0.27 | 0.10 | 0.09 | 0.04 | 0.52 | — |
| Debt / assets | 0.34 | 0.14 | 0.07 | 0.08 | 0.03 | 0.32 | — |
| Current ratio | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Quick ratio | 4.84 | 5.58 | 2.53 | 11.10 | 4.67 | 2.75 | 1.19 |
| Interest coverage | — | — | — | -9.6 | -1.0 | -0.1 | — |
| Working capital | $143.8M | $173.9M | $86.6M | $269.9M | $212.6M | $34.0M | $1.4M |
| Invested capital | $59.6M | $3.5M | $25.0M | $51.1M | −$19.7M | −$2.3M | −$7.3M |
| Tangible asset value | $120.9M | $153.1M | $133.1M | $316.3M | $239.6M | $33.5M | $1.4M |
| Net current asset value | −$40.6M | $67.5M | $82.2M | $252.6M | $208.3M | $32.1M | $1.4M |
| Graham net-net per share | −$0.30 | $0.39 | $0.67 | $2.57 | $2.17 | $0.33 | $0.01 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | — | — | — |
| Capex / revenue | 97.8% | 244.5% | — | 308.9% | — | 12.3% | — |
| Capex / depreciation | 0.84 | 1.19 | 1.87 | 7.24 | 7.31 | 14.86 | 14.86 |
| Stock-based compensation / revenue | 631.9% | 873.9% | — | 124.0% | — | 7.5% | — |
| R&D / revenue | 3,468.0% | 5,205.8% | — | 1,664.6% | — | 57.2% | — |
| SG&A / revenue | 1,130.1% | 1,681.6% | — | 572.3% | — | 60.7% | — |
| Efficiency | |||||||
| Days payables outstanding | 504.5 | 919.9 | 936.2 | 87.6 | 63.3 | 30.6 | — |
| Payables turnover | 0.72 | 0.40 | 0.39 | 4.17 | 5.77 | 11.92 | — |
| Asset turnover | 0.01 | 0.01 | 0.00 | 0.02 | 0.00 | 0.16 | 0.00 |
| Average payables | $10.1M | $15.4M | $11.9M | $2.9M | $842,500 | $250,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PRME's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PRME valuation and financial ratios
Prime Medicine earned a return on equity of −146.8% and a return on invested capital of −521.6% in fiscal 2025. It ended the year with $116.4 million of debt and $177.7 million in cash and short-term investments, a net cash position of $61.3 million. The share count rose 55.4% from 95.7M to 148.8M over 6 years.
See the PRME income statement, the PRME chart for price history, or the PRME stock overview for the latest quote and news.
PRME key metrics FAQ
What is Prime Medicine's return on equity?
Prime Medicine's return on equity (ROE) was −146.8% in fiscal 2025: net income of -$201.1 million on average shareholders' equity of $137.0 million.
What is Prime Medicine's ROIC?
Prime Medicine's return on invested capital was −521.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Prime Medicine have?
Prime Medicine had total debt of $116.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.96 and more cash than debt.
What is Prime Medicine's free cash flow yield?
Prime Medicine generated -$167.1 million of free cash flow in fiscal 2025, a free cash flow yield of −32.4% on its market value at year-end ($516.2 million).
What is Prime Medicine's current ratio?
Prime Medicine's current ratio was 4.84 at the end of fiscal 2025: current assets were 4.84 times current liabilities.